A guide for healthcare organizations to harness big data

Laura Pedulli | | Health Exec | Digital Transformation

 

Healthcare organizations can employ a number of strategies to utilize big data to improve quality of care and outcomes for patients, especially those with chronic conditions, according to Hospitals & Health Networks.

The article describes five ways a healthcare organization can work with patients, and with their data, to build a better care model: (1) Make the patient a responsible member of the healthcare team; (2) Think ahead to a holistic approach to data acquisition and analysis; (3) Remove the noise; (4) Let the data inform task automation; and (5) Better facilitate feedback from providers to patients.

Read more below:


How Health Care Organizations Can Get More Out of Big Health Data

Laura Pedulli

Related Content

10 signs AI is ‘eating the world (of venture capital)’
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy
Healthcare AI regulation needs nuance, balance: Research review
ICU diary-keeping: There’s an AI for that
Stanford HAI lookback: Best-read blog posts of 2024
Providers, payers share actionable experiences involving healthcare AI

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.